Agios Pharmaceuticals, Inc. (AGIO) News
Filter AGIO News Items
AGIO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AGIO News Highlights
- For AGIO, its 30 day story count is now at 23.
- Over the past 23 days, the trend for AGIO's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- DRUG, PK and PFE are the most mentioned tickers in articles about AGIO.
Latest AGIO News From Around the Web
Below are the latest news stories about Agios Pharmaceuticals Inc that investors may wish to consider to help them evaluate AGIO as an investment opportunity.
Agios Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call PresentationThe following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with their 2021 Q4 earnings call.... |
Agios (AGIO) Loss Wider Than Expected in Q4, Revenues NilAgios Pharmaceuticals (AGIO) posts wider-than-expected loss for the fourth quarter of 2021. It does not record any revenues in the quarter. |
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara BiotherapeuticsRegeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog. |
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Lags Revenue EstimatesAgios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -5.85% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Agios Reports Fourth Quarter and Full Year 2021 Financial Results– Received FDA Approval of PYRUKYND® (mitapivat) for the Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase (PK) Deficiency; First Approved Therapy for this Rare Blood Disorder – – First Patients Dosed in All Three Pivotal Trials of PYRUKYND® in Thalassemia and Sickle Cell Disease – – Cash, Cash Equivalents and Marketable Securities $1.3 Billion as of Dec. 31; Expects Strong Cash Position to Enable Execution of Robust Operating Plan to Cash-Flow Positivity – CAMBRIDGE, Mass., Feb. 24, |
Agios Pharmaceuticals With FDA Approval Is A BuyAgios Pharmaceuticals (AGIO) specializes in creating therapies for diseases related to cellular metabolism. Its first approved drug was Idhifa, which was approved for treating IDH mutation driven cancers, in 2017. That was followed by approval of Tibsovo for acute myeloid leukemia in 2018. In 2021 Agios sold its cancer therapy... |
Biotech Stock Roundup: SAGE, ATRA Down on Study Updates, AGIO Drug Approval & MoreUpdates from SAGE and Atara (ATRA) are among a few key highlights from the biotech sector during the past week. |
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News FlowBiotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug Administration approved Agios Pharmaceuticals, Inc.''s (NASDAQ: AGIO ) mitapivat for treating pyruvate kinase deficiency, a rare, inherited metabolic disorder. Avenue Therapeutics, Inc. (NASDAQ: ATXI ) stock tumbled close to 60% after an FDA panel found that data included in the company''s new drug application for pain drug tramadol was inadequate to support approval. GlaxoSmithKline plc (NYSE: GSK ) and Sanofi (NASDAQ: SNY )- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) suffered setbacks after their respective late-stage studies of respiratory syncytial vaccine candidate in pregnant wome... |
Agios Pyrukynd for rare blood disorder gets US FDA approvalThe U.S. Food and Drug Administration ((FDA)) approved Agios Pharmaceuticals'' (AGIO) Pyrukynd (mitapivat) to treat hemolytic anemia in adults with pyruvate kinase ((PK))… |
Agios stock gains as H.C. Wainwright raises target on FDA approval (NASDAQ:AGIO)Agios Pharmaceuticals (AGIO) is trading ~2% higher in the pre-market on Friday as Wall Street reacts to the FDA approval for the company’s oral PK activator Pyrukynd (mitapivat) to… |